HIV/HBV co-infection remodels the immune landscape and Natural Killer cell ADCC functional responses.


Journal

Hepatology (Baltimore, Md.)
ISSN: 1527-3350
Titre abrégé: Hepatology
Pays: United States
ID NLM: 8302946

Informations de publication

Date de publication:
30 Apr 2024
Historique:
received: 10 11 2023
accepted: 23 01 2024
medline: 30 4 2024
pubmed: 30 4 2024
entrez: 30 4 2024
Statut: aheadofprint

Résumé

HBV and HIV co-infection is a common occurrence globally, with significant morbidity and mortality. Both viruses lead to immune dysregulation including changes in NK cells, a key component of antiviral defense and a promising target for HBV cure strategies. Here we used high-throughput single cell analysis to explore the immune cell landscape in people with HBV mono-infection and HIV/HBV co-infection, on antiviral therapy, with emphasis on identifying the distinctive characteristics of NK cell subsets that can be therapeutically harnessed. Our data show striking differences in the transcriptional programs of NK cells. HIV/HBV co-infection was characterized by an overrepresentation of adaptive, KLRC2 expressing NK cells, including a higher abundance of a chemokine enriched (CCL3/CCL4) adaptive cluster. The NK cell remodeling in HIV/HBV co-infection was reflected in enriched activation pathways, including CD3ζ phosphorylation and ZAP-70 translocation that can mediate stronger ADCC responses and a bias towards chemokine/cytokine signaling. By contrast HBV mono-infection imposed a stronger cytotoxic profile on NK cells and a more prominent signature of 'exhaustion' with higher circulating levels of HBsAg. Phenotypic alterations in the NK cell pool in co-infection were consistent with increased 'adaptiveness' and better capacity for ADCC compared to HBV mono-infection. Overall, an adaptive NK cell signature correlated inversely with circulating levels of HBsAg and HBV-RNA in our cohort. This study provides new insights into the differential signature and functional profile of NK cells in HBV and HIV/HBV co-infection, highlighting pathways that can be manipulated to tailor NK cell-focused approaches to advance HBV cure strategies in different patient groups.

Sections du résumé

BACKGROUND BACKGROUND
HBV and HIV co-infection is a common occurrence globally, with significant morbidity and mortality. Both viruses lead to immune dysregulation including changes in NK cells, a key component of antiviral defense and a promising target for HBV cure strategies. Here we used high-throughput single cell analysis to explore the immune cell landscape in people with HBV mono-infection and HIV/HBV co-infection, on antiviral therapy, with emphasis on identifying the distinctive characteristics of NK cell subsets that can be therapeutically harnessed.
RESULTS RESULTS
Our data show striking differences in the transcriptional programs of NK cells. HIV/HBV co-infection was characterized by an overrepresentation of adaptive, KLRC2 expressing NK cells, including a higher abundance of a chemokine enriched (CCL3/CCL4) adaptive cluster. The NK cell remodeling in HIV/HBV co-infection was reflected in enriched activation pathways, including CD3ζ phosphorylation and ZAP-70 translocation that can mediate stronger ADCC responses and a bias towards chemokine/cytokine signaling. By contrast HBV mono-infection imposed a stronger cytotoxic profile on NK cells and a more prominent signature of 'exhaustion' with higher circulating levels of HBsAg. Phenotypic alterations in the NK cell pool in co-infection were consistent with increased 'adaptiveness' and better capacity for ADCC compared to HBV mono-infection. Overall, an adaptive NK cell signature correlated inversely with circulating levels of HBsAg and HBV-RNA in our cohort.
CONCLUSIONS CONCLUSIONS
This study provides new insights into the differential signature and functional profile of NK cells in HBV and HIV/HBV co-infection, highlighting pathways that can be manipulated to tailor NK cell-focused approaches to advance HBV cure strategies in different patient groups.

Identifiants

pubmed: 38687604
doi: 10.1097/HEP.0000000000000877
pii: 01515467-990000000-00870
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for the Study of Liver Diseases.

Auteurs

Bo Sun (B)

Nuffield Department of Clinical Neurosciences, University of Oxford, United Kingdom.

Kelly A S da Costa (KAS)

Division of Infection and Immunity, University College London, London, United Kingdom.

Aljawharah Alrubayyi (A)

Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom.

Jonida Kokici (J)

Division of Infection and Immunity, University College London, London, United Kingdom.

Natasha Fisher-Pearson (N)

Nuffield Department of Clinical Medicine, University of Oxford, United Kingdom.

Noshin Hussain (N)

Division of Infection and Immunity, University College London, London, United Kingdom.

Stefano D'Anna (S)

University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy.

Lorenzo Piermatteo (L)

University of Rome Tor Vergata, Department of Biology, Rome, Italy.

Romina Salpini (R)

University of Rome Tor Vergata, Department of Experimental Medicine, Rome, Italy.

Valentina Svicher (V)

University of Rome Tor Vergata, Department of Biology, Rome, Italy.

Stephanie Kucykowicz (S)

Division of Infection and Immunity, University College London, London, United Kingdom.

Indrajit Ghosh (I)

Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, United Kingdom.

Fiona Burns (F)

The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, UK.
Institute for Global Health, University College London, UK.

Sabine Kinloch (S)

The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, UK.

Pedro Simoes (P)

The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, UK.

Sanjay Bhagani (S)

Division of Infection and Immunity, University College London, London, United Kingdom.
Department of HIV Medicine, Royal Free Hospital NHS Foundation Trust, UK.

Patrick T F Kennedy (PTF)

Barts Liver Centre, Barts & The London School of Medicine & Dentistry, QMUL.

Mala K Maini (MK)

Division of Infection and Immunity, University College London, London, United Kingdom.

Rachael Bashford-Rogers (R)

Department of Biochemistry, University of Oxford, UK.

Upkar S Gill (US)

Barts Liver Centre, Barts & The London School of Medicine & Dentistry, QMUL.

Dimitra Peppa (D)

Division of Infection and Immunity, University College London, London, United Kingdom.
Mortimer Market Centre, Department of HIV, CNWL NHS Trust, London, United Kingdom.
The Ian Charleson Day Centre, Royal Free Hospital NHS Foundation Trust, UK.

Classifications MeSH